Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Middle East Tech Today.
Press releases published on May 9, 2025
Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health
GlobeNewswire
·
May 9, 2025
PURCHASE, N.Y., May 09, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, reported preclinical data this week at the Association for Research in Vision …
Spectral Medical Announces First Quarter and Provides Corporate Update
GlobeNewswire
·
May 9, 2025
Tigris Trial Enrollment completed Topline results expected to be released in August 2025 Entered into an up to US$10 million Promissory Note with Vantive to Fund Spectral to PMX commercialization TORONTO, May 09, 2025 (GLOBE NEWSWIRE) -- Spectral Medical …
UPCX Dubai 2049 KOL TOUR Review: Reliving the Desert, Real Connections
GlobeNewswire
·
May 9, 2025
Singapore, May 09, 2025 (GLOBE NEWSWIRE) -- On May 2, 2025, beneath the golden dunes of Dubai, a distinctive Web3 gathering quietly unfolded. Following the success of the inaugural “Proof of Connect” event in Bangkok, AllSpark Research once again joined …
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine
GlobeNewswire
·
May 9, 2025
Results support potential benefit of efruxifermin (EFX) to elicit fibrosis improvement in patients with compensated cirrhosis (F4 fibrosis) due to MASH 96-week data from SYMMETRY trial presented at EASL Congress 2025 SOUTH SAN FRANCISCO, Calif., May 09, …
uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress
GlobeNewswire
·
May 9, 2025
~ AMT-130 granted Breakthrough Therapy designation by FDA ~ ~ Initial safety data from third cohort of Phase I/II study show AMT-130 continues to be generally well-tolerated, with no treatment-related serious adverse events ~ ~ Held Type B FDA meetings in …
Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting
GlobeNewswire
·
May 9, 2025
ALPHARETTA, Ga., May 09, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS …
Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases
GlobeNewswire
·
May 9, 2025
IRF5 program strengthens Kymera’s oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug IRF5, a historically undrugged transcription factor and master …
Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series
GlobeNewswire
·
May 9, 2025
WAYNE, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Aclaris’ Chief …
OXB to Present at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
GlobeNewswire
·
May 9, 2025
OXB to Present at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) Oxford, UK – 9 May 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces its participation in the 28th Annual …
Aya Gold & Silver Reports April Production as Zgounder Ramp Up Gains Momentum
GlobeNewswire
·
May 9, 2025
MONTREAL, May 09, 2025 (GLOBE NEWSWIRE) -- Aya Gold & Silver Inc. (TSX: AYA; OTCQX: AYASF) (“Aya” or the “Corporation”) is pleased to report continued operational progress at its Zgounder Silver Mine, driven by a strong mine ramp up, exceptional mill …
Bitdeer Announces April 2025 Production and Operations Update
GlobeNewswire
·
May 9, 2025
SINGAPORE, May 09, 2025 (GLOBE NEWSWIRE) -- Bitdeer Technologies Group (NASDAQ: BTDR) (“Bitdeer” or the “Company”), a world-leading technology company for Bitcoin mining, today announced its unaudited mining and operations updates for April 2025. …
Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab
GlobeNewswire
·
May 9, 2025
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a …
Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025
GlobeNewswire
·
May 9, 2025
CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the …
Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update
GlobeNewswire
·
May 9, 2025
Completed KT-621 (STAT6) SAD/MAD Phase 1 healthy volunteer trial with data to be reported in June 2025 First patient dosed in KT-621 (STAT6) BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) with data expected in 4Q25 KT-579 (IRF5) new …
Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights
GlobeNewswire
·
May 9, 2025
Initial proof-of-concept data from the ongoing BBI-355 Phase 1/2 POTENTIATE trial in patients with oncogene-amplified cancers anticipated in the second half of 2025 Novel Kinesin program on track for mid-2025 development candidate nomination and IND filing …
ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance
GlobeNewswire
·
May 9, 2025
Generated record quarterly net revenues of $197.1 million, representing year-over-year growth of 43.4% Total Rare Disease quarterly net revenues of $69.0 million, which includes: Purified Cortrophin® Gel net revenues of $52.9 million, an increase of 43.1% …
Castellum, Inc. Reports First Year-Over-Year Organic Revenue Growth with Q1 2025 Results
GlobeNewswire
·
May 9, 2025
VIENNA, Va., May 09, 2025 (GLOBE NEWSWIRE) -- Castellum, Inc. ("Castellum" or the "Company") (NYSE-American: CTM), a cybersecurity, electronic warfare, and software services company focused on the federal government, announces certain highlights of its …
Outbrain Announces First Quarter 2025 Results
GlobeNewswire
·
May 9, 2025
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Outbrain Inc. (Nasdaq: OB), which is operating under the new Teads brand following Outbrain’s acquisition of Teads in February 2025, announced today financial results for the quarter ended March 31, 2025. First …
Gravity Reports First Quarter of 2025 Results and Business Update
GlobeNewswire
·
May 9, 2025
Seoul, South Korea, May 09, 2025 (GLOBE NEWSWIRE) -- GRAVITY Co., Ltd. (NasdaqGM: GRVY) (“Gravity” or “Company”), a developer and publisher of online and mobile games based in South Korea, today announced its unaudited financial results for the first …
Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025
GlobeNewswire
·
May 9, 2025
SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, presented …